ESMO 2025 Conference Review – Breast Cancer Focus

In this review:
– POSITIVE: updated 5-year results
– monarchE: updated results of adjuvant abemaciclib + endocrine therapy in HR+, HER2–, high-risk early breast cancer
– NATALEE: 5-year outcomes of ribociclib + NSAI in stage I/III, HR+, HER2− early breast cancer
– OptiTROP-Breast02: sac-TMT in pre-treated, advanced, HR+, HER2– breast cancer
– evERA BD: second-line giredestrant + everolimus in ER+, HER2– advanced breast cancer
– VIKTORIA-1: second-line gedatolisib + fulvestrant ± palbociclib in HR+, HER2–, PIK3CA wild-type advanced breast cancer
– DESTINY-Breast11: neoadjuvant T-DXd-THP versus SOC for high-risk, HER2+ early breast cancer
– DESTINY-Breast05: post-neoadjuvant T-DXd vs. T-DM1 in high-risk, HER2+ early breast cancer
– ASCENT-03: sacituzumab govitecan (SG) in advanced TNBC ineligible for PD-(L)1 inhibitors
– TROPION-Breast02: Dato-DXd vs. chemotherapy in metastatic TNBC ineligible for immunotherapy